Chen, a 54-year-old man, once led a peaceful, ordinary life—until an unexpected illness shattered everything. At first, he only felt a dull blockage when swallowing food, accompanied by intermittent swelling and pain on the left side of his neck. He dismissed the symptoms as mere inflammation from internal heat and paid them no mind. But as discomfort worsened day by day, eating became agonizing, prompting him to rush to hospital for examinations.

Test results delivered a devastating blow. Nasopharyngoscope biopsy confirmed squamous cell carcinoma of the tongue base with cervical lymph node metastasis. Immune profiling revealed extremely low PD-L1 expression, meaning single-agent immunotherapy offered little therapeutic benefit. PET-CT uncovered even grimmer news: active primary tumor remained at the tongue base, bilateral cervical lymph nodes were riddled with metastases, and cancer cells had spread to the iliac and ischial bones, diagnosing stage IV advanced tongue base carcinoma. His treatment hurdles emerged immediately. Doctors first administered multi-agent combination chemotherapy with cisplatin and paclitaxel. However, severe side effects including persistent nausea and overwhelming fatigue proved unbearable, forcing Chen to discontinue treatment after just one cycle. He then switched to single-agent targeted therapy with nimotuzumab. After five cycles, neck masses shrank and pain temporarily subsided, giving Chen a fleeting glimmer of hope. Yet relief was short-lived: three months after stopping medication, cervical tumors regrew rapidly, and excruciating pain returned, making eating and drinking unbearable.

By this point, Chen had exhausted all standard treatment options. Conventional chemotherapy and targeted therapy had failed entirely, while his PD-L1 negativity rendered traditional immunotherapy largely ineffective. As his family sank into despair, doctors presented a new lifeline—Tumor-Infiltrating Lymphocyte (TIL) cell therapy. This treatment harnesses the patient’s own immune cells extracted from tumor tissue to recognize and attack cancer cells without reliance on fixed molecular targets, making it an ideal fit for Chen’s clinical profile. But another critical obstacle arose. Generating potent, functional therapeutic immune cells required harvesting a minimum of 1 cubic centimeter of viable, non-necrotic tumor tissue. Chen’s lesions carried extreme procedural risks: metastatic lymph nodes adhered tightly to major cervical blood vessels with dense vascular networks, and large areas within the masses had liquefied and necrosed. Conventional surgical biopsy could trigger life-threatening massive hemorrhage. Furthermore, enlarged lymph nodes compressed the airway, creating severe risks of asphyxia and failed postoperative extubation under general anesthesia—tumor tissue sampling became a critical, high-stakes challenge for the care team.

The hospital immediately convened a multidisciplinary team (MDT) consultation, bringing together specialists from head and neck surgery, ultrasound, radiology, pathology, cell therapy, anesthesiology, and critical care medicine to design a customized, safe tissue harvesting protocol for Chen. Head and neck surgeons mapped the complex anatomical relationship between lesions and blood vessels and ruled out invasive open biopsy. Radiology and ultrasound specialists cross-analyzed contrast-enhanced CT and contrast-enhanced ultrasound scans repeatedly, identifying a solid, viable, persistently enhanced tumor region on the lateral aspect of the lymph node. Real-time contrast-enhanced ultrasound visualization enabled minimally invasive puncture to precisely avoid blood vessels and necrotic tissue. The anesthesiology team opted for full local anesthesia to completely eliminate airway asphyxia risks. The cell therapy center set strict puncture criteria to retrieve long strips of sufficient tumor tissue using a thick biopsy needle, while the pathology department stood by for rapid assessment of tissue viability. Critical care staff prepped a full emergency hemorrhage management kit to mitigate all foreseeable risks in advance.

All departments finalized a unified care plan: Chen enrolled in the GT307 clinical trial and underwent minimally invasive puncture under contrast-enhanced ultrasound guidance with local anesthesia to safely acquire tumor tissue for TIL cell production. On the day of sampling, clinicians used three-dimensional contrast-enhanced ultrasound imaging to map a puncture trajectory that bypassed all blood vessels and directly targeted viable tumor tissue. Real-time contrast monitoring guided needle angle adjustments throughout the procedure, which lasted only 20 minutes. Six intact tumor tissue strips each over 1 centimeter long were successfully harvested. Rapid pathological testing delivered encouraging results: tumor cells accounted for over 60% of the specimen, and tissue viability met all manufacturing requirements for cell therapy. Post-procedure scans showed no bleeding or leakage. Over 24 hours of observation, Chen experienced no dizziness, hematoma, dyspnea, or worsening cervical pain. The harvested tumor tissue was immediately transported to a standardized GMP-grade cell laboratory. A series of precise processes—tissue homogenization, enzymatic digestion, and multiple rounds of cell expansion—were performed over 35 days to produce qualified TIL cell infusion product. While waiting for cell expansion, the MDT team administered bridging chemotherapy combining cisplatin and nimotuzumab to halt cancer progression. The regimen caused only mild adverse reactions, and follow-up scans confirmed stable tumor lesions, securing a critical treatment window without delaying subsequent cell infusion.

Once the cell product passed full quality inspection, Chen entered the lymphodepletion conditioning phase with fludarabine plus cyclophosphamide chemotherapy. This regimen depleted endogenous circulating lymphocytes to create a supportive in vivo microenvironment for the infused therapeutic immune cells. Chen tolerated conditioning well, presenting only mild leukopenia without severe complications such as infection or bleeding. With all preparations complete, Chen was transferred to a sterile laminar airflow ward. Cryopreserved TIL cells were thawed in a water bath and slowly infused intravenously. Twelve hours post-infusion, interleukin-2 (IL-2) supportive therapy was initiated. He experienced transient fever and chills during treatment, which resolved rapidly with symptomatic intervention; no dangerous adverse effects including pulmonary edema or hypotension occurred. Shortly after successful cell transfusion, Chen’s months-long cervical swelling and pain diminished markedly, and his overall physical condition steadily improved, allowing him to be discharged soon afterward. One-month follow-up scans brought tremendous joy to his family: the primary tongue base tumor and all cervical metastatic lymph nodes remained stable, bone metastasis-related aching was drastically alleviated, and all visceral organ functions were preserved intact. Today, Chen enjoys unrestricted daily mobility and tolerates semi-liquid diets normally, with drastically improved quality of life. He only needs routine follow-up visits to monitor persistent TIL activity and tumor dynamics as prescribed.

From a hopeless situation with no remaining standard treatments to minimally invasive precision tissue sampling and cutting-edge cell therapy supported by seamless multidisciplinary collaboration, Chen’s case represents not only a milestone in anti-tumor treatment but also a heartwarming story of doctors and patients united in the battle against cancer. Sophisticated cross-department coordination and breakthroughs in contrast-enhanced ultrasound minimally invasive techniques have restored a fighting chance at survival for patients with high-risk late-stage malignancies.